Core Viewpoint - The National Medical Insurance Administration is transforming its role from traditional fund management to a strategic hub that connects public health needs with pharmaceutical industry development, emphasizing dual functions of "social security + innovation empowerment" [1][2]. Group 1: Fund Support and Expenditure - During the 14th Five-Year Plan period, the total expenditure of the medical insurance fund is projected to reach 13 trillion yuan, with an average annual growth of 10%, providing stable financial support for innovation [2]. - The adjustment cycle for the medical insurance catalog has been compressed from 8 years to 1 year, focusing on new drugs launched within the last 5 years, with 98% of new effective drugs expected to be included in the catalog by 2024 [2]. - Over the past 8 years, more than 900 new drugs have been added, with 80% of new drugs being included in the payment scope within 2 years of their market launch, driving drug sales exceeding 600 billion yuan [2]. Group 2: Price Governance and Innovation Support - The establishment of the first national drug price registration network aims to achieve low drug prices through centralized procurement and catalog negotiations, while also supporting the application of innovative technologies such as surgical robots and digital customized imaging [2]. - The medical insurance department has proactively focused on the development of cutting-edge medical technologies, with the support process for brain-computer interface technology serving as a typical example [2][3]. - In March 2025, the medical insurance department established pricing and charging standards for brain-computer interfaces, addressing payment challenges for technology applications [2]. Group 3: Future Outlook and Strategic Initiatives - The medical insurance department is also incorporating a range of new technologies and drugs, such as remote operations, proton heavy ion therapy, and CAR-T tumor treatment, into its support framework, ensuring that the public benefits from innovative outcomes [3]. - The department is actively building international platforms to promote Chinese pharmaceutical innovations globally, while real-world comprehensive value evaluation serves as crucial evidence for medical insurance decision-making [3]. - Looking ahead to the 15th Five-Year Plan, the medical insurance department will continue to deepen its dual-driven strategy of "policy guidance" and "value evaluation," optimizing payment policies for innovative technologies like brain-computer interfaces [3].

Group 1 - The National Healthcare Security Administration (NHSA) has included 79 hospitals in the national credible evaluation point network for real-world healthcare value assessment [2] - The NHSA aims to ensure the credibility of evaluations by involving credible evaluation points in three key areas: entry assessment, data verification, and quality assurance [2][3] - The NHSA emphasizes the importance of professional personnel from credible evaluation points to assist in reviewing evaluation proposals to ensure they meet scientific and clinical needs [2] Group 2 - The NHSA plans to enhance data authenticity by inviting credible evaluation points to participate in checks and verify original data, addressing any identified deficiencies [2] - The NHSA encourages credible evaluation points to engage in peer evaluations to maintain the quality of assessments and produce trustworthy evaluation reports [2] - The NHSA aims to establish an information-sharing mechanism among credible evaluation points to improve the efficiency and quality of healthcare evaluations [3]

Core Viewpoint - The establishment of the National Trustworthy Evaluation Point Network for Real-World Medical Insurance Comprehensive Value Evaluation aims to create a scientific and authoritative evaluation standard to support healthcare policy-making through reliable data [1][2]. Group 1: Network Formation - A total of 79 medical institutions have signed the "National Trustworthy Evaluation Point Network Agreement for Real-World Medical Insurance Comprehensive Value Evaluation" in Beijing [1]. - The network will be responsible for the comprehensive value evaluation of medical insurance, assisting healthcare departments in making informed decisions [1]. Group 2: Evaluation Objectives - The initiative seeks to objectively and accurately identify the clinical benefits and comprehensive value of medical products, relying on credible data [2]. - Historically, the assessment of the value of medical products and services has depended on authoritative conclusions from relevant departments and clinical experts, which has limitations [2]. Group 3: Pilot Program - In September of last year, the National Healthcare Security Administration announced the launch of a pilot program for real-world medical insurance comprehensive value evaluation [2].

Core Viewpoint - The establishment of the National Credible Evaluation Point Network for Real-World Medical Insurance Comprehensive Value Evaluation aims to create a scientific and authoritative evaluation standard to objectively identify the clinical benefits and comprehensive value of medical products, supporting the formulation and decision-making of medical insurance policies [1] Group 1 - The National Healthcare Security Administration's Deputy Director, Shi Zihai, emphasized the importance of credible data in the evaluation process, highlighting the role of medical institutions in data generation, standard formulation, and research [1] - A total of 79 leading medical institutions, including Peking University People's Hospital, signed the "National Credible Evaluation Point Network Agreement" in Beijing, marking the formation of the National Credible Evaluation Point Network [1] - The network of medical institutions will take on the responsibility of real-world medical insurance comprehensive value evaluation, assisting the healthcare department in making scientific decisions [1]

Core Viewpoint - The National Healthcare Security Administration (NHSA) has signed agreements with 79 hospitals to initiate a pilot program for real-world comprehensive value assessment of medical insurance, aiming to evaluate the effectiveness, safety, and economic value of pharmaceutical products post-market [1] Group 1: Real-World Research and Evaluation - Real-world research refers to the assessment of the effectiveness, safety, and economic value of medical products based on data generated from daily clinical practices [1] - The NHSA acknowledges that while a dynamic adjustment mechanism for the medical insurance catalog is in place, challenges remain in decision-making due to the idealized conditions of pre-market clinical trials [1][6] - The evaluation will incorporate patient experiences and satisfaction, addressing the discrepancies between clinical trial populations and the broader patient population [3] Group 2: Data Collection and Analysis - Comprehensive data collection will include patient demographics, treatment plans, clinical outcomes, and adverse effects of medications [5] - Real-world data can reveal complexities and uncertainties, such as the actual incidence of side effects that may differ from clinical trial results [8] - The use of real-world data will enable clearer insights into which medications genuinely improve patient quality of life and which medical services offer better cost-effectiveness [8] Group 3: Implications for Healthcare Funding - The real-world comprehensive value assessment is expected to enhance the efficiency of healthcare fund allocation, allowing for the identification and exclusion of high-cost, low-efficacy drugs [10] - This approach aims to create a more patient-centered healthcare system by prioritizing innovative technologies and services that meet actual patient needs [10]

Core Viewpoint - The establishment of the "National Credible Evaluation Point Network for Real-World Comprehensive Value Assessment of Medical Insurance" marks a significant step in integrating real-world data into China's medical insurance decision-making process, creating a new "value metric" for evaluating the clinical effectiveness and overall impact of medical products on patient quality of life and resource allocation [1][2][4]. Group 1: Establishment of the Network - A total of 79 medical institutions signed the agreement to form the credible evaluation point network, which will play a crucial role in supporting scientific decision-making for medical insurance [1][2]. - The network is designed to be open and dynamic, allowing for the inclusion of additional institutions based on their research achievements and contributions to the evaluation process [6]. Group 2: Evaluation Framework - The National Medical Insurance Administration has drafted guidelines for the real-world comprehensive value assessment of drugs, which outline the evaluation objects, processes, and methodological frameworks [2][5]. - The shift from traditional theoretical models to evaluations based on clinical real-world data signifies a transformation in the medical insurance evaluation system [2]. Group 3: Impact on Medical Institutions - Medical institutions involved in the network will be responsible for generating data, establishing standards, and conducting research, thereby playing an irreplaceable role in the evaluation process [4][6]. - The network aims to fill the gap in real-world research that has previously been lacking, ensuring that the clinical application of drugs and medical supplies is adequately studied [6]. Group 4: Future Implications for Pharmaceutical Companies - Real-world comprehensive value assessments will provide objective evidence for medical insurance decision-making, influencing the dynamic adjustment of the medical insurance catalog [9]. - Pharmaceutical companies are encouraged to conduct real-world studies during the critical period between clinical trials and drug applications to provide more evidence for insurance decisions [9][10]. - The establishment of incentive mechanisms linked to insurance negotiations will motivate pharmaceutical companies to engage in real-world value assessments, impacting future negotiations and payment standards [10].

Core Insights - The establishment of the National Credible Evaluation Point Network for Real-World Medical Insurance Comprehensive Value Assessment aims to scientifically evaluate the actual value of pharmaceutical products using real clinical data [1][2] - The initiative involves 79 leading medical institutions and is intended to support key decisions in medical insurance, including drug negotiations and pricing [1] - The network will provide objective evidence for the adjustment of the medical insurance catalog, ensuring that the benefits and cost-effectiveness of negotiated drugs are in line with initial expectations [1] Group 1 - The Real-World Research focuses on evaluating the effectiveness, safety, and economic value of pharmaceutical products based on data generated from daily clinical practices [1] - The National Healthcare Security Administration (NHSA) emphasizes the importance of real-world research as a foundational work for medical insurance decision-making [1] - The NHSA plans to conduct evaluations every two years for negotiated drugs to ensure their benefits align with expectations [1] Group 2 - The NHSA aims for each credible evaluation point to participate in at least one real-world comprehensive value assessment of a drug, consumable, or medical service by 2026 [2] - The initiative is expected to generate demonstrable results that can withstand scrutiny and be applied in practical scenarios [2]

Core Viewpoint - The establishment of the National Credible Evaluation Point Network aims to enhance the scientific decision-making of medical insurance departments through real-world comprehensive value evaluation of medical products [1] Group 1: Establishment and Purpose - 79 medical institutions have signed the "National Credible Evaluation Point Network Convention" to form the National Credible Evaluation Point Network [1] - The initiative is designed to create a scientific and authoritative evaluation standard based on real and credible data to objectively identify the clinical benefits and comprehensive value of medical products [1] Group 2: Role of Medical Institutions - Medical institutions represented by the credible evaluation points will play an irreplaceable role in data generation, standard formulation, and research [1] - The network members will lead a series of comprehensive value evaluation studies based on the needs of medical insurance decision-making and application scenarios [1] Group 3: Collaboration and Future Research - The medical insurance department encourages collaboration with various institutions, including the National Credible Evaluation Point Network, to conduct research that supports scientific decision-making in medical insurance [1]

Core Viewpoint - The establishment of the National Trustworthy Evaluation Point Network marks a significant step in supporting scientific decision-making in healthcare insurance through real-world research [1][4]. Group 1: Establishment of the Network - 79 medical institutions, including Peking University People's Hospital and Shanghai Sixth People's Hospital, have signed the National Trustworthy Evaluation Point Network Agreement [1]. - The network aims to create a scientific and authoritative evaluation standard based on real and credible data to objectively identify the clinical benefits and comprehensive value of medical products [1][4]. Group 2: Role of Trustworthy Evaluation Points - Trustworthy evaluation points will play an irreplaceable role in data generation, standard formulation, and research execution [1][4]. - The network is expected to contribute to the establishment of a value-oriented, real-world research-based comprehensive evaluation system for healthcare insurance over the next three years [4]. Group 3: Data Quality and Evaluation Process - High-quality data accumulation, scientific research design, and rigorous evaluation systems are essential for forming credible evidence [4]. - Multi-disciplinary expert involvement is necessary throughout the process to ensure the quality of evidence that can be adopted in decision-making [4]. Group 4: Future Directions and Collaboration - The National Healthcare Security Administration will guide trustworthy evaluation points to collect information regularly and share innovative ideas and solutions [5]. - The network is designed to be open and dynamic, allowing for the inclusion of outstanding external research institutions and the adjustment of non-compliant institutions [5].

Core Insights - The National Healthcare Security Administration has issued a notice to initiate pilot programs for real-world comprehensive value assessment of medical insurance in select regions including Haidian District of Beijing, Dalian City of Liaoning Province, and Shenzhen City of Guangdong Province [1] Group 1: Pilot Program Details - The pilot regions will focus on research directions such as comprehensive value assessment of drugs based on real-world data, unmet clinical needs research, and how healthcare data can support real-world studies [1] - The research outcomes will support healthcare decision-making and encourage pilot regions to prioritize the application of these findings for new or adjusted medical consumables charging directories and new medical service project approvals [1] Group 2: Future Goals - By the end of 2027, the pilot regions aim to establish a value-oriented, real-world research-based comprehensive value assessment system for medical insurance, which will be promoted nationwide [1]